Published in PLoS One on December 05, 2007
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res (2008) 2.48
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov (2012) 1.50
A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol (2009) 1.48
An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia (2010) 1.31
Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia (2008) 1.29
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer (2015) 1.27
Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin Cancer Res (2010) 1.16
Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome. Br J Dermatol (2011) 1.13
Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia. Cancer Res (2009) 1.08
MEK genomics in development and disease. Brief Funct Genomics (2012) 1.04
MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. Clin Cancer Res (2014) 1.02
Mek1/2 gene dosage determines tissue response to oncogenic Ras signaling in the skin. Oncogene (2009) 0.94
Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development. RNA (2014) 0.92
Genetics of melanoma. Front Genet (2013) 0.91
Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood (2016) 0.89
PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse. BMC Cancer (2012) 0.86
Molecular and functional analysis of a novel MEK2 mutation in cardio-facio-cutaneous syndrome: transmission through four generations. Am J Med Genet A (2010) 0.86
The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models. PLoS One (2011) 0.84
Mechanisms of aneuploidy induction by RAS and RAF oncogenes. Am J Cancer Res (2011) 0.84
Differential regulation of Smad3 and of the type II transforming growth factor-β receptor in mitosis: implications for signaling. PLoS One (2012) 0.83
Multiplexed tracking of combinatorial genomic mutations in engineered cell populations. Nat Biotechnol (2015) 0.81
OVARIAN CANCER SUICIDE GENE THERAPY WITH GENETICALLY ENGINEERED, TRANSGENICALLY EXPRESSED, INTRACELLULAR scFv ANTIBODIES AGAINST ANTI-OXIDATIVE ENZYMES. Proc S Dak Acad Sci (2008) 0.80
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res (2015) 0.79
In vivo severity ranking of Ras pathway mutations associated with developmental disorders. Proc Natl Acad Sci U S A (2017) 0.77
CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo. Carcinogenesis (2013) 0.77
VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation. Br J Cancer (2017) 0.75
Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight (2017) 0.75
Somatic MAP2K1 Mutations Are Associated with Extracranial Arteriovenous Malformation. Am J Hum Genet (2017) 0.75
Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms. Hematol Oncol Clin North Am (2017) 0.75
Pre-clinical evaluation of a themosensitive gel containing epothilone B and mTOR/Hsp90 targeted agents in an ovarian tumor model. J Control Release (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res (2003) 52.26
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet (2006) 9.80
The RAF proteins take centre stage. Nat Rev Mol Cell Biol (2004) 8.04
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res (2006) 6.91
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet (2005) 6.70
Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer (2004) 6.07
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors (2006) 5.58
Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res (2005) 4.14
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther (2006) 4.09
Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science (2006) 3.96
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet (2006) 3.69
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene (1999) 3.32
In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol (2004) 3.08
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol (2005) 2.83
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther (2006) 2.76
Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults. Genes Chromosomes Cancer (2006) 2.50
Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res (1985) 2.50
Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim (2000) 1.91
Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet (2007) 1.89
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol (2003) 1.74
Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res (2003) 1.70
Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res (2004) 1.66
PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat (2005) 1.61
A novel regulatory mechanism in the mitogen-activated protein (MAP) kinase cascade. Role of nuclear export signal of MAP kinase kinase. J Biol Chem (1997) 1.55
Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res (1991) 1.39
Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352. Mol Cell Biol (2002) 1.28
Mitogen-activated protein (MAP) kinase phosphorylation of MAP kinase kinase: determination of phosphorylation sites by mass spectrometry and site-directed mutagenesis. J Biochem (1994) 1.24
Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome. Am J Med Genet A (2007) 1.18
Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer (2000) 1.16
A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol (2005) 1.04
A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol (2004) 1.02
PIK3CA mutations in ovarian cancer. Clin Cancer Res (2005) 0.86
Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors. Pathol Int (2000) 0.85
Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations. Genes Chromosomes Cancer (1997) 0.84
Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines. Oncogene (1997) 0.84
Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors. Cancer Genet Cytogenet (1999) 0.81
Single mutations of the PTEN gene in recurrent ovarian carcinomas. J Soc Gynecol Investig (2000) 0.78
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
The RB and p53 pathways in cancer. Cancer Cell (2002) 8.02
Chromosome aberrations in solid tumors. Nat Genet (2003) 7.01
The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev (2009) 5.53
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med (2008) 5.19
Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev (2003) 4.89
Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell (2003) 4.32
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res (2005) 3.98
Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science (2006) 3.96
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
Ras signaling and therapies. Adv Cancer Res (2009) 2.93
Advocacy groups as research organizations: the PXE International example. Nat Rev Genet (2007) 2.72
Therapeutic strategies for targeting ras proteins. Genes Cancer (2011) 2.45
Combinatorial patterns of somatic gene mutations in cancer. FASEB J (2008) 2.40
Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer (2004) 2.32
The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med (2009) 2.29
A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell (2005) 2.27
Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol (2004) 2.27
Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst (2007) 2.23
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res (2008) 2.20
SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A (2003) 2.12
Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res (2004) 2.09
Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene (2005) 2.06
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell (2004) 2.05
A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS One (2006) 2.05
Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell (2005) 1.96
Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene (2003) 1.93
Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene (2004) 1.93
RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell (2013) 1.89
The molecular pathology of cancer. Nat Rev Clin Oncol (2010) 1.86
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell (2013) 1.73
Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res (2003) 1.70
A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol Cell (2006) 1.68
EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal (2009) 1.66
DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS One (2010) 1.65
Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway. Expert Rev Mol Med (2008) 1.64
An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res (2004) 1.64
Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov (2012) 1.62
Tpr directly binds to Mad1 and Mad2 and is important for the Mad1-Mad2-mediated mitotic spindle checkpoint. Genes Dev (2008) 1.59
Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat (2007) 1.56
A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia (2004) 1.54
Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene (2004) 1.52
Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res (2002) 1.50
Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication. EMBO J (2005) 1.47
Skp2 suppresses p53-dependent apoptosis by inhibiting p300. Mol Cell (2008) 1.45
DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res (2008) 1.42
HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A (2006) 1.39
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell (2010) 1.35
A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev (2012) 1.33
p97/DAP5 is a ribosome-associated factor that facilitates protein synthesis and cell proliferation by modulating the synthesis of cell cycle proteins. EMBO J (2006) 1.28
Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci U S A (2013) 1.27
Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome. Am J Med Genet A (2011) 1.24
Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov (2013) 1.22
Neurological complications of cardio-facio-cutaneous syndrome. Dev Med Child Neurol (2007) 1.22
Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. Cancer Res (2004) 1.22
Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res (2003) 1.21
Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene (2005) 1.20
Healing full-thickness cartilage defects using adipose-derived stem cells. Tissue Eng (2007) 1.19
Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell (2002) 1.18
Surgeons' attitudes are associated with reoperation and readmission rates. Clin Orthop Relat Res (2015) 1.17
Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res (2006) 1.15
Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Hum Mol Genet (2009) 1.13
What effects have resident work-hour changes had on education, quality of life, and safety? A systematic review. Clin Orthop Relat Res (2015) 1.13
Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome. Methods Enzymol (2008) 1.12
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One (2012) 1.11
Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res (2005) 1.11
Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology (2002) 1.10
Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet (2011) 1.10
Ovarian cancer early detection claims are biased. Clin Cancer Res (2008) 1.10
Killing time for cancer cells. Nat Rev Cancer (2005) 1.08
Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther (2002) 1.07
Cardio-facio-cutaneous syndrome phenotype and del(12q). Am J Med Genet A (2003) 1.07
Cloning and characterization of a functional promoter of the human SOCS-3 gene. Biochem Biophys Res Commun (2003) 1.07
MDMX inhibits the p300/CBP-mediated acetylation of p53. DNA Cell Biol (2002) 1.06
Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology (2005) 1.06
Genomic alterations that contribute to the development of isolated and non-isolated congenital diaphragmatic hernia. J Med Genet (2011) 1.05
The RasGAP proteins Ira2 and neurofibromin are negatively regulated by Gpb1 in yeast and ETEA in humans. Mol Cell Biol (2010) 1.03
War wounds: lessons learned from Operation Iraqi Freedom. Plast Reconstr Surg (2008) 1.03
Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther (2005) 1.03
Phosphorylation of p16INK4A correlates with Cdk4 association. J Biol Chem (2003) 1.00
Cloning and characterization of the promoter of human Wnt inhibitory factor-1. Biochem Biophys Res Commun (2004) 0.99
Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells. J Mol Med (Berl) (2004) 0.98
Role for PP2A in ARF signaling to p53. Proc Natl Acad Sci U S A (2004) 0.98
Ring chromosome 15: characterization by array CGH. Hum Genet (2005) 0.97
Mad2 inhibits the mitotic kinesin MKlp2. J Cell Biol (2010) 0.97
Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther (2006) 0.97
Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish. Dis Model Mech (2012) 0.96
Patient safety climate among orthopaedic surgery residents. J Bone Joint Surg Am (2011) 0.96
Surgical management of complex proximal humerus fractures-a systematic review of 92 studies including 4500 patients. J Orthop Trauma (2015) 0.96
Autism traits in the RASopathies. J Med Genet (2013) 0.95
Adenovirus overrides cellular checkpoints for protein translation. Cell Cycle (2005) 0.94
Molecular aspects, clinical aspects and possible treatment modalities for Costello syndrome: Proceedings from the 1st International Costello Syndrome Research Symposium 2007. Am J Med Genet A (2008) 0.93
Wnt-1 signal as a potential cancer therapeutic target. Drug News Perspect (2006) 0.92
Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. Hum Mol Genet (2007) 0.91
Cytogenetic and array CGH characterization of de novo 1p36 duplications and deletion in a patient with congenital cataracts, hearing loss, choanal atresia, and mental retardation. Am J Med Genet A (2008) 0.91
Critical role for arginine methylation in adenovirus-infected cells. J Virol (2007) 0.90
A prospective analysis of 179 type 2 superior labrum anterior and posterior repairs: outcomes and factors associated with success and failure. Am J Sports Med (2013) 0.90